Previous 10 | Next 10 |
Immix Biopharma ( NASDAQ: IMMX ) said it in-licensed a BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101). The company added that has formed a wholly-owned subsidiary called Nexcella to develop and potentially commercialize NXC-201. The drug had shown ...
Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff ( Haematologica https://doi.org/10.3324/haematol.2022.281628 ) AL Amyloidosis - 100% complete r...
Immix Biopharma ( NASDAQ: IMMX ) is trading ~7% higher premarket after it announced patient dosing in an ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. The company expects IMX-110 clinical trial data to be released on a rolling basis beginning in Q1 2023. Once dos...
In December 2022, the 15 th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110 combi...
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology...
Immix Biopharma ( NASDAQ: IMMX ) on Friday said it had got an approval from an institutional review board to enroll children in its upcoming clinical trial of its IMX-110 therapy for the treatment of rhabdomyosarcoma. Rhabdomyosarcoma is a rare type of cancer that forms i...
Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a...
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, ...
California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT sca...
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tum...
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for: EU protocol assistance, marketing authorization applications, inspections bef...